Page 230 - Vitamin D and Cancer

9 Molecular Biology of Vitamin D Metabolism and Skin Cancer 217

97. Li C, Liu Z, Zhang Z et al (2007) Genetic variants of the vitamin D receptor gene alter risk
of cutaneous melanoma. J Invest Dermatol 127(2):276–280
98. Lips P (2006) Vitamin D physiology. Prog Biophys Mol Biol 92(1):4–8
99. Lo PK, Huang SZ, Chen HC et al (2004) The prosurvival activity of p53 protects cells from
UV-induced apoptosis by inhibiting c-Jun NH2-terminal kinase activity and mitochondrial
death signaling. Cancer Res 64(23):8736–8745
100. Losel R, Wehling M (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol
4(1):46–56
101. Luscombe CJ, French ME, Liu S et al (2001) Outcome in prostate cancer associations with
skin type and polymorphism in pigmentation-related genes. Carcinogenesis
22(9):1343–1347
102. Marks R, Foley PA, Jolley D et al (1995) The effect of regular sunscreen use on vitamin D
levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol
131(4):415–421
103. Masuda S, Jones G (2003) Vitamin D analogs–drug design based on proteins involved in vita-
min D signal transduction. Curr Drug Targets Immune Endocr Metabol Disord 3(1):43–66
104. Matsumoto K, Azuma Y, Kiyoki M et al (1991) Involvement of endogenously produced 1,
25-dihydroxyvitamin D-3 in the growth and differentiation of human keratinocytes. Biochim
Biophys Acta 1092(3):311–318
105. Matsuoka LY, Ide L, Wortsman J et al (1987) Sunscreens suppress cutaneous vitamin D3
synthesis. J Clin Endocrinol Metab 64(6):1165–1168
106. Miller GJ, Stapleton GE, Hedlund TE et al (1995) Vitamin D receptor expression, 24-hy-
droxylase activity, and inhibition of growth by 1alpha, 25-dihydroxyvitamin D3 in seven
human prostatic carcinoma cell lines. Clin Cancer Res 1(9):997–1003
107. Muindi JR, Modzelewski RA, Peng Y et al (2004) Pharmacokinetics of 1alpha, 25-
dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor
doses. Oncology 66(1):62–66
108. Murayama A, Kim MS, Yanagisawa J et al (2004) Transrepression by a liganded nuclear
receptor via a bHLH activator through co-regulator switching. Embo J 23(7):1598–1608
109. Murayama A, Takeyama K, Kitanaka S et al (1998) The promoter of the human 25-hy-
droxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to
PTH, calcitonin, and 1 alpha, 25(OH)2D3. Biochem Biophys Res Commun 249(1):11–16
110. Nakajima S, Hsieh JC, MacDonald PN et al (1994) The C-terminal region of the vitamin D
receptor is essential to form a complex with a receptor auxiliary factor required for high
affinity binding to the vitamin D-responsive element. Mol Endocrinol 8(2):159–172
111. Nemere I (2005) The 1, 25D3-MARRS protein: contribution to steroid stimulated calcium
uptake in chicks and rats. Steroids 70(5–7):455–457
112. Nemere I, Yoshimoto Y, Norman AW (1984) Calcium transport in perfused duodena from
normal chicks: enhancement within fourteen minutes of exposure to 1, 25-dihydroxyvitamin
D3. Endocrinology 115(4):1476–1483
113. Norman AW (2006) Minireview: vitamin D receptor: new assignments for an already busy
receptor. Endocrinology 147(12):5542–5548
114. Norman AW, Bouillon R, Farach-Carson MC et al (1993) Demonstration that 1 beta, 25-di-
hydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses
and biological profile of the three A-ring diastereomers of 1 alpha, 25-dihydroxyvitamin D3.
J Biol Chem 268(27):20022–20030
115. Norman AW, Henry HL, Bishop JE et al (2001) Different shapes of the steroid hormone
1alpha, 25(OH)(2)-vitamin D(3) act as agonists for two different receptors in the
vitamin D endocrine system to mediate genomic and rapid responses. Steroids 66(3–5):
147–158
116. Nowson CA, Diamond TH, Pasco JA et al (2004) Vitamin D in Australia. Issues and recom-
mendations. Aust Fam Physician 33(3):133–138
117. Oda Y, Sihlbom C, Chalkley RJ et al (2003) Two distinct coactivators, DRIP/mediator and
SRC/p160, are differentially involved in vitamin D receptor transactivation during keratinocyte
differentiation. Mol Endocrinol 17(11):2329–2339